Cypress Capital Group lessened its holdings in Pfizer Inc. (NYSE:PFE) by 0.7% during the fourth quarter, HoldingsChannel reports. The firm owned 93,996 shares of the biopharmaceutical company’s stock after selling 652 shares during the quarter. Cypress Capital Group’s holdings in Pfizer were worth $4,103,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also made changes to their positions in PFE. Oregon Public Employees Retirement Fund boosted its stake in shares of Pfizer by 5,652.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 100,090,541 shares of the biopharmaceutical company’s stock worth $2,293,000 after acquiring an additional 98,350,629 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Pfizer by 2.7% during the 4th quarter. BlackRock Inc. now owns 462,846,797 shares of the biopharmaceutical company’s stock worth $20,203,263,000 after acquiring an additional 12,167,126 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Pfizer by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 75,208,911 shares of the biopharmaceutical company’s stock worth $3,277,414,000 after acquiring an additional 7,055,791 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of Pfizer by 1.5% during the 3rd quarter. Vanguard Group Inc now owns 441,792,969 shares of the biopharmaceutical company’s stock worth $19,469,816,000 after acquiring an additional 6,620,749 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Pfizer by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 441,792,969 shares of the biopharmaceutical company’s stock worth $19,469,816,000 after acquiring an additional 6,620,749 shares in the last quarter. 71.88% of the stock is currently owned by institutional investors.
PFE stock opened at $42.76 on Friday. Pfizer Inc. has a 1 year low of $35.73 and a 1 year high of $46.47. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.27 and a current ratio of 1.54. The company has a market capitalization of $237.74 billion, a P/E ratio of 14.25, a P/E/G ratio of 2.49 and a beta of 0.65.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.10. The company had revenue of $13.12 billion during the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a return on equity of 27.48% and a net margin of 21.31%. Pfizer’s revenue was up 1.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.77 EPS. Analysts expect that Pfizer Inc. will post 2.89 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Friday, June 7th. Shareholders of record on Friday, May 10th were issued a $0.36 dividend. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.44 annualized dividend and a yield of 3.37%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.
Several brokerages have recently commented on PFE. Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, April 10th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $46.00 price target on shares of Pfizer in a research note on Friday, April 19th. Bank of America boosted their price target on Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Morgan Stanley began coverage on Pfizer in a research note on Tuesday, June 4th. They set an “overweight” rating and a $48.00 price target on the stock. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $53.00 price target on shares of Pfizer in a research note on Tuesday, February 19th. Thirteen research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $46.00.
In other Pfizer news, major shareholder Pfizer Inc purchased 50,000 shares of the business’s stock in a transaction on Monday, May 13th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $850,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $42.83, for a total value of $642,450.00. Following the completion of the transaction, the insider now owns 124,994 shares of the company’s stock, valued at $5,353,493.02. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Cypress Capital Group Has $4.10 Million Holdings in Pfizer Inc. (NYSE:PFE)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2019/06/15/cypress-capital-group-has-4-10-million-holdings-in-pfizer-inc-nysepfe.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: How are dividend achievers different from dividend aristocrats?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.